Bloating, abdominal pain, diarrhea, and nausea are standard IBS complaints. They are also standard MCAS complaints. The difference is what happens outside the gut. Mast cell activation syndrome is an immune disorder in which mast cells release histamine, prostaglandins, leukotrienes, and other mediators inappropriately, producing reactions across multiple organ systems at once. When those reactions center on the GI tract, the result looks exactly like IBS. But when flushing, hives, brain fog, or a racing heart show up alongside the gut symptoms, the picture shifts. Understanding where IBS ends and MCAS begins can change the diagnosis and the treatment plan entirely.
What is MCAS?
Mast cell activation syndrome is a condition in which mast cells, immune cells found throughout the body but concentrated in the skin, gut lining, airways, and around blood vessels, become hyperreactive. In healthy people, mast cells respond to genuine threats like infections or allergens. In MCAS, they degranulate in response to triggers that should not provoke an immune reaction: temperature changes, stress, certain foods, exercise, or sometimes nothing identifiable at all. When mast cells degranulate, they release mediators including histamine, tryptase, prostaglandin D2, and leukotrienes. These mediators cause inflammation, vasodilation, smooth muscle contraction, and mucus secretion across whichever tissues are affected.
The 2012 consensus criteria proposed by Valent and colleagues require three elements for MCAS diagnosis: episodic symptoms consistent with mast cell mediator release affecting two or more organ systems, documented elevation of mast cell mediators (most commonly serum tryptase) during or shortly after a symptomatic episode, and clinical improvement with medications that block or inhibit mast cell mediators. Meeting all three criteria distinguishes MCAS from other conditions that produce overlapping symptoms.
How do IBS and MCAS symptoms overlap?
The GI symptoms of MCAS are often indistinguishable from IBS when viewed in isolation. Both produce abdominal pain, bloating, diarrhea, constipation, nausea, and food-triggered symptom flares. A gastroenterologist evaluating only GI complaints has no way to tell them apart based on symptoms alone. The overlap is not coincidental. Mast cells are abundant in the intestinal mucosa. When they degranulate in the gut, they cause smooth muscle spasm, altered motility, increased intestinal permeability, and visceral hypersensitivity, all mechanisms implicated in IBS pathophysiology.
| Symptom | IBS | MCAS |
|---|---|---|
| Abdominal pain | Core diagnostic criterion | Common, often episodic |
| Bloating | Very common | Very common, often with visible distension |
| Diarrhea | IBS-D subtype | Common during flares |
| Nausea | Occasional | Frequently accompanies flares |
| Skin flushing | Not typical | Common, especially face and chest |
| Hives or rashes | Not typical | Common, may be triggered by heat or stress |
| Brain fog | Reported by some patients | Common during and after flares |
| Tachycardia | Not typical | Common, especially with concurrent POTS |
| Food triggers | Variable, often high-FODMAP | Often histamine-rich foods specifically |
What are the key differentiators?
The critical distinction between IBS and MCAS is multi-system involvement. IBS is defined as a GI disorder. MCAS affects multiple organ systems simultaneously or in sequence. If your gut symptoms consistently appear alongside non-GI symptoms, the pattern points toward mast cell activation rather than IBS alone.
- Multi-system symptom episodes. MCAS flares typically involve two or more organ systems at once. A typical episode might include abdominal cramping with facial flushing and a sudden headache, or diarrhea with hives and a racing heart. IBS flares are confined to the GI tract.
- Histamine-rich food triggers. In MCAS, aged cheeses, fermented foods (sauerkraut, kimchi, kombucha), wine and beer, cured or smoked meats, canned fish, and vinegar-containing foods are common triggers. While IBS patients may react to high-FODMAP foods, the histamine-specific trigger pattern is more characteristic of mast cell involvement.
- Dermatologic symptoms. Flushing (red blotches on the face, neck, or chest), hives (urticaria), dermatographism (skin writing, where scratching produces raised welts), and angioedema (localized swelling) are mast cell mediator effects. These do not occur in IBS.
- Cardiovascular symptoms. Tachycardia, lightheadedness, and presyncope during symptom flares point to histamine-mediated vasodilation and are not part of the IBS symptom profile. The overlap with POTS is well-documented.
- Neurologic symptoms. Brain fog, difficulty concentrating, anxiety, and irritability during flares are driven by histamine's effects on the central nervous system. While IBS patients report fatigue and mood changes, the acute cognitive impairment during MCAS flares has a different temporal pattern, appearing and resolving with the episode.
The MCAS-EDS-POTS triad
An increasingly recognized clinical pattern links MCAS with Ehlers-Danlos syndrome (EDS, particularly the hypermobile type) and postural orthostatic tachycardia syndrome (POTS). Patients with one of these conditions frequently have one or both of the others. Cheung and colleagues documented this overlap in a 2023 systematic review, noting that the triad appears in a significant subset of patients originally diagnosed with single-system disorders. The connection matters for IBS diagnosis because EDS-related connective tissue laxity can cause structural GI problems, POTS causes autonomic dysfunction that affects gut motility, and MCAS causes the immune-mediated GI symptoms described above. A patient with all three may present to a gastroenterologist with bloating, pain, and diarrhea, receive an IBS diagnosis, and have three contributing conditions that require different treatments.
âšī¸If you have been diagnosed with hypermobile EDS or POTS and also carry an IBS diagnosis, ask your doctor whether MCAS evaluation is warranted. The triad is common enough that screening for all three conditions when one is identified is considered reasonable practice.
The MCAS and SIBO connection
Weinstock and colleagues reported in 2021 that MCAS patients have approximately three times the prevalence of SIBO compared to the general population. The proposed mechanisms include mast cell mediator effects on gut motility (histamine and prostaglandins alter smooth muscle contraction patterns), the impact of concurrent connective tissue disorders on GI structural integrity, and the autonomic dysfunction that often accompanies MCAS through its association with POTS. This means some patients labeled with IBS may actually have MCAS-driven dysmotility that has led to secondary SIBO. Treating the SIBO alone without addressing the mast cell component results in recurrence because the underlying cause of the motility disruption remains active.
How are IBS and MCAS diagnosed differently?
IBS is diagnosed using the Rome IV symptom criteria with no confirmatory laboratory test. MCAS diagnosis requires objective evidence of mast cell mediator elevation. The primary diagnostic tests include serum tryptase measured during a symptomatic episode (a rise of at least 20% above the patient's personal baseline plus 2 ng/mL), 24-hour urinary N-methylhistamine, 24-hour urinary prostaglandin D2 or its metabolite 11-beta-prostaglandin F2 alpha, and urinary leukotriene E4. Testing must be timed to symptomatic episodes, which makes MCAS harder to capture than conditions with stable biomarkers. A single normal tryptase drawn during a symptom-free interval does not rule out MCAS.
| Feature | IBS | MCAS |
|---|---|---|
| Diagnostic method | Symptom criteria (Rome IV) | Mediator testing + clinical criteria |
| Confirmatory lab test | None | Serum tryptase, urinary metabolites |
| Organ systems involved | GI only | Multi-system (GI, skin, cardiovascular, neurologic) |
| Triggers | Variable (stress, foods, hormones) | Histamine-rich foods, heat, stress, exercise |
| Treatment approach | Symptom management | Mast cell stabilizers, H1/H2 antihistamines |
How do treatment approaches differ?
IBS treatment focuses on symptom management through dietary modification (low-FODMAP), antispasmodics, fiber, and gut-brain modulators. MCAS treatment targets the mast cells directly. First-line MCAS therapy typically includes H1 antihistamines (cetirizine, loratadine, or fexofenadine) combined with H2 antihistamines (famotidine). Mast cell stabilizers like cromolyn sodium (oral form, taken before meals) can reduce GI-specific mast cell degranulation. Leukotriene inhibitors (montelukast) may be added for patients with incomplete response. In more severe cases, omalizumab (anti-IgE monoclonal antibody) or low-dose aspirin (as a prostaglandin inhibitor) may be considered. A low-histamine diet replaces the low-FODMAP diet as the primary dietary strategy, though some patients benefit from combining elements of both.
The treatment difference is clinically meaningful. A patient with MCAS-driven GI symptoms who is managed with antispasmodics and a low-FODMAP diet will likely remain symptomatic because the mast cell degranulation driving their symptoms is not being addressed. Conversely, the same patient on H1/H2 antihistamines and cromolyn sodium may see significant improvement within weeks.
Frequently Asked Questions
Can you have both IBS and MCAS?
Yes. MCAS can cause GI symptoms that meet IBS diagnostic criteria. In some patients, treating the MCAS resolves the IBS symptoms entirely. In others, IBS and MCAS coexist as separate conditions with overlapping GI manifestations. Treating the mast cell component first often clarifies what residual symptoms remain.
What does an MCAS flare feel like compared to an IBS flare?
An MCAS flare typically involves multiple body systems at once. You might experience abdominal cramping alongside facial flushing, itching, brain fog, or a rapid heart rate. An IBS flare is generally limited to GI symptoms: pain, bloating, diarrhea, or constipation. The multi-system nature of MCAS flares is the most distinguishing feature.
Does a normal tryptase level rule out MCAS?
No. Tryptase must be measured during or within 1-4 hours of a symptomatic episode and compared to the patient's personal baseline. A tryptase drawn when you are feeling fine tells you nothing about mast cell activation during flares. Many MCAS patients have normal baseline tryptase with elevations only during episodes.
Should I try a low-histamine diet before getting tested?
A low-histamine diet trial can provide useful clinical information, but it should not replace formal testing. If you notice significant improvement on a low-histamine diet, that supports the possibility of mast cell involvement and strengthens the case for formal MCAS evaluation. Discuss this with your doctor before modifying your diet.
What type of doctor diagnoses MCAS?
Allergists and immunologists are the specialists most likely to diagnose and manage MCAS. Some gastroenterologists and hematologists are familiar with the condition. If your gastroenterologist is not addressing your non-GI symptoms, a referral to an allergist/immunologist experienced in mast cell disorders is a reasonable next step.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.